Pfizer (PFE) CFO Denton awarded 216,537 stock appreciation rights

Rhea-AI Filing Summary

Pfizer Inc. reported that Chief Financial Officer and EVP David M. Denton received a grant of 216,537 Stock Appreciation Rights on March 3, 2026. These awards were acquired at a stated price of $0.00 per right, reflecting an equity-based compensation grant rather than an open-market purchase.

The footnote explains that the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. Following this grant, Denton’s reported direct derivative holdings in these rights total 216,537.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Denton David M

Role Chief Financial Officer & EVP

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights	216,537	$0.00	--

Holdings After Transaction: Stock Appreciation Rights — 216,537 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Denton David M

(Last) (First) (Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK NY 10001-2192

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer & EVP

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$26.58	03/03/2026		A		216,537		03/03/2031(1)	03/03/2031(1)	Common Stock	216,537	$0.0000	216,537	D

Explanation of Responses:

1. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

	/s/ Shanice A. Reid, by power of atty, for David M. Denton	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pfizer (PFE) report for David M. Denton?

Pfizer reported that CFO and EVP David M. Denton received a grant of 216,537 Stock Appreciation Rights. The grant reflects equity-based compensation and not an open-market share purchase, and it increases his reported direct derivative holdings in these rights to 216,537.

How many Stock Appreciation Rights were granted to Pfizer (PFE) CFO Denton?

David M. Denton was granted 216,537 Stock Appreciation Rights. This entire amount is newly acquired under a single award on March 3, 2026, and represents his total reported holdings in this specific derivative position following the transaction.

At what price were David M. Denton’s Pfizer (PFE) Stock Appreciation Rights granted?

The Stock Appreciation Rights granted to David M. Denton carry a reported transaction price of $0.00 per right. This indicates a compensation award structure, where value depends on future stock performance rather than an upfront cash purchase by the executive.

When will David M. Denton’s Pfizer (PFE) Stock Appreciation Rights be settled?

The Stock Appreciation Rights will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. Settlement timing is therefore tied to this future date and subject to the vesting requirements described in the accompanying footnote.

Do David M. Denton’s Pfizer (PFE) Stock Appreciation Rights have vesting conditions?

Yes. The footnote states that the Stock Appreciation Rights are subject to certain vesting requirements. Only after satisfying these conditions will the rights be settled in Pfizer common stock on the fifth anniversary of the March 3, 2026 grant date.

Is David M. Denton’s Pfizer (PFE) Form 4 transaction a stock purchase or a compensation grant?

The Form 4 shows a compensation grant, not a market purchase. The transaction code is “A” for grant or award, the direction is classified as acquisition, and the Stock Appreciation Rights were reported at a transaction price of $0.00 per right.